The latest updates from OTCMarkets | Not displaying properly? Click here
November 15, 2016
OTCQX Market Highlights in 2016

Watch OTC Markets EVP Jason Paltrowitz discuss enhancements we’ve made to the OTCQX Best Market – all in support of our goal to make being public less painful. We look forward to continuing to expand these efforts and announce new programs in 2017. 

  • Higher Data-Driven Standards & Stronger Governance: Our prohibition of penny stocks as well as our higher mandatory minimum bid price and market cap standards, and best practice corporate governance standards ensure that investors can rely on the OTCQX designation.
  • Access to Research: Investors looking to analyze and benchmark OTCQX securities now have access to globally recognized quantitative research through our collaboration with Morningstar. The launch of our Research Marketplace is an additional resource for companies to provide high quality third-party research coverage to investors.
  • Streamlined Compliance: The maturity of the market, higher standards and strength of our compliance team has allowed us to remove the ongoing OTCQX Advisor formal compliance role and the red tape of the annual letter requirement. Inclusion in a securities manual is also no longer required for OTCQX companies – an additional time and cost saving initiative.
  • Regulatory Recognition: We now have 13 states recognizing securities on the OTCQX Best Market for Blue Sky Manual exemptions. We will continue to work with state regulators, in partnership with OTCQX companies, to achieve nationwide Blue Sky recognition.
  • Information Availability: Our Compliance Data File was recognized by the industry for enabling broker-dealers and clearing firms to more easily and efficiently trade OTCQX securities and to distinguish them from less transparent companies.
  • Timely Share Data: The Transfer Agent Verified Shares Program launched as a new initiative designed to ensure investors can access accurate and timely share data on OTCQX companies.
  • Visibility: We’ve increased the size and scope of our Community Spotlight, OTCQX Virtual Investor Conferences, and CEO Interviews, reaching 30,000+ investors to date. OTCQX is well tailored for a future of finance that is online, data-driven and social.
Amendments to OTCQX Rules

Effective January 1st, new rules for OTCQX companies will remove the ongoing formal role of the OTCQX Advisor, PAL or Corporate Broker, including the responsibility of submitting the Annual Letter after a company begins trading on OTCQX.  As our markets have grown, we have improved the financial and governance standards, increased the size of our compliance and market surveillance teams and have strengthened our ongoing disclosure monitoring infrastructure, enabling us to efficiently take on the process of OTCQX company ongoing eligibility review and financial standards verification.

We believe these OTCQX Rule changes will further our goals of using technology and transparency to create the best informed and most efficient public trading markets in a cost-effective manner. OTCQX Rules Release No. 13.

Transfer Agent
Transfer Agent Verified Shares Program

ClearTrust, Direct Transfer LLC and Olde Monmouth Stock Transfer have joined VStock Transfer as participants in the Transfer Agent Verified Shares Program, an initiative to improve the accuracy and reliability of share information for OTCQX, OTCQB and Pink securities. Verified share data for their issuer clients is available on and via market data feeds. Learn more.

Community Spotlight

Deborah Rathjen, CEO of
Bionomics Ltd. (OTCQX: BNOEF)

“We are combining one of the world’s most innovative drug discovery platforms with development of novel, best-in-class therapies. Our management team has extensive expertise in drug discovery and development in large opportunity markets in oncology and CNS.”


OTC Markets Group (OTCM): Tell us about your company.

Deborah Rathjen: Bionomics is a clinical stage biopharmaceutical company leveraging proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates focused on the treatment of diseases of serious central nervous system disorders and on the treatment of cancer. The Company’s lead candidate BNC210, is a novel, orally-administered drug for the treatment of anxiety and depression. Bionomics’ lead oncology candidate, BNC101 is a first-in-class antibody targeting cancer stem cells, in development for the treatment of colon cancer and other solid tumors.

Click here to read the full interview.

OTCM: What were your major accomplishments for the last year?

Ms. Rathjen: In September, we announced positive results from our Phase 2 trial of BNC210 in Generalized Anxiety Disorder (GAD). The single center, double-blinded, placebo and lorazepam-controlled, 4-way cross-over Phase 2 clinical trial was conducted in 24 patients with untreated GAD. The objective of the study was to evaluate the capacity of BNC210 to engage brain systems relevant to anxiety while resting and in response to anxiety-related tasks. The co-primary endpoints were change in cerebral perfusion measured by arterial spin labelling and change in task-related brain activity, specifically in the amygdala as measured by functional Magnetic Resonance Imaging (fMRI) during the Emotional Faces Task (EFT). Results from the study showed that BNC210 induced statistically significant changes in cerebral perfusion (300mg BNC210, p<0.05) and also significantly reduced amygdala activation in response to fearful faces during the EFT (300mg BNC210, p<0.05). In comparison, lorazepam exerted a modest suppressive effect on amygdala activation during performance of the EFT (1.5mg lorazepam, p=0.069). Earlier this year, we initiated a Phase 2 clinical trial of BNC210 for the treatment of Post-Traumatic Stress Disorder (PTSD) and expect topline data from this trial in 2018.

In March, we initiated a Phase 1 study of BNC101 for the treatment of metastatic colorectal cancer. The open label, multi-center clinical trial in patients with metastatic colorectal cancer will aim to demonstrate that BNC101 is safe and well tolerated and that it is able to delay disease relapse in treated patients. The trial will be conducted at specialist centres across Australia and will run in two parts, firstly with BNC101 alone and then in combination with standard of care chemotherapy. Each part has two phases, an escalation to find the optimal dose level and then an expansion of the study at that dose level.

OTCM: What differentiates your company and what is your strategy for growth going forward?

Ms. Rathjen: Bionomics is a fully integrated biotechnology company that has created proprietary technology platforms, which include ionX, MultiCore and CSCRx, for each step in the drug discovery and development process. Each of these advanced technologies is a source of competitive advantage offering the company the opportunity to identify and progress unique new pharmaceutical products. Additionally, the Company has a lengthy history of successful partnerships with industry and academia. Most notably, we have a strategic partnership with Merck utilizing the ionX and MultiCore platforms in two preclinical stage programs. Merck has an option to exclusively license for development and commercialization certain small molecule drug candidates for the treatment of chronic and neuropathic pain. Under the agreement, Bionomics may receive up to $172 million in exercise fees and milestone payments, in addition to royalties on product sales. We also have a research collaboration and license agreement with Merck to develop compounds targeting cognitive impairment in conditions such as Alzheimer’ s disease, Parkinson’s disease, schizophrenia and attention deficit disorder, or ADHD, for which we received a $20 million upfront payment and may receive up to an additional $486 million in research and milestone payments, in addition to royalties on product sales. Moving forward we will look to continue to build strategic partnerships so that we can focus our strengths on innovative drug discovery.

OTCM: You trade on the ASX in Australia and on OTCQX in the U.S. What is your strategy for reaching investors?

Ms. Rathjen: Bionomics regularly attends investor conferences across the globe with the aim to maintain regular investor interactions. Additionally, Bionomics has research coverage in Australia and the United States from Darren Vincent (Shaw and Partners), Tanushree Jain (Bell Potter) and Joe Pantginis (Roth Capital Partners). Furthermore, while Bionomics is based in Adelaide, Australia, the Company has operations in San Diego, USA and a wholly owned subsidiary in Strasbourg, France, which allows us to maximize our efforts meeting with investors.

OTCM: What else do you want investors to know about your company?

Ms. Rathjen: We are combining one of the world’s most innovative drug discovery platforms with development of novel, best-in-class therapies. Our management team has extensive expertise in drug discovery and development in large opportunity markets in oncology and CNS. The Company is well financed with a cash balance of AUD$44.5M (as of 30 June 2016) to support our business objectives.

Click to close.

OTCQX Video Series
OTCQX Video Series

Fuat Erbil, CEO & President of Turkiye Garanti Bankasi A.S. (BIST: GARAN; LSE: TGBD; 39IS; OTCQX: TKGBY; TKGBF), the second largest private bank in Turkey, speaks with Jason Paltrowitz, OTC Markets EVP of Corporate Services, in our latest video.
Watch Now.

OTC Markets Blog
OTC Markets Blog

Don't Be Pound Foolish

Which US Equity Market has the largest number of securities NOT considered Penny Stocks according to SEC Rule 3a51-1? Based on the location of this post, you should be able to guess...but that should make it no less surprising.  The numbers speak for themselves. Read more.

Blue Sky Recognition for OTCQX and OTCQB

Arkansas became the 13th state to recognize OTCQX and OTCQB for the purposes of "Blue Sky Manual Exemption" for secondary trading. The other states that have recognized our premium markets include: Alaska, Colorado, Georgia, Kansas, Iowa, Mississippi, Nebraska, New Mexico, Rhode Island, Vermont, Washington and Wyoming. 

New OTCQX Canada Index Launches

The OTCQX Canada Index (.OTCQXCAN), a new performance benchmark for Canadian companies on the OTCQX market, launched in October. The index tracks the performance of high-quality, investor-focused companies that are cross-traded on the OTCQX market in the U.S. and on the Toronto Stock Exchange (TSX), TSX Venture Exchange or Canadian Securities Exchange (CSE) in Canada. These companies represent a wide range of industries from metals and mining to life sciences and biotechnology.  Learn more.

Monthly Trade Summary - October 2016
Market Designations Number
of Securities*
$ Volume
Monthly $ Volume
per Security
YTD $ Volume*
OTCQX 453 $2,962,883,135 $6,540,580 $29,600,083,653
OTCQB 931 $924,019,823 $992,502 $6,989,773,817
Pink 8,235 $10,619,823,670 $1,289,596 $113,589,692,723
Total 9,619 $14,506,726,629 $1,508,132 $150,179,550,195

*Data as of October 31, 2016


Community Banks Webinar Series: Blue Sky Laws & Secondary Trading Overview (Nov. 15, 2016)

2016 STANY International Reception and Holiday Party – New York, NY (Nov. 17, 2016)

IR Society: Best Practice Awards Dinner – London, UK (Nov. 22, 2016)

Webinar: The Value of Equity Research with Edison Research Group & OTC Markets (Dec. 1, 2016)

LD Micro – Los Angeles, CA (Dec. 6-8, 2016)

Crowd Invest Summit – Los Angeles, CA (Dec. 7-8, 2016)

Bank Director’ s 23rd Annual Acquire or Be Acquired Conference –Phoenix, AZ (Jan. 29-31, 2017)

IR Magazine Awards – Toronto, Canada (Feb. 2, 2017)

Please contact for more information.

Archived Webcast of the OTC Markets Presentation

OTC Markets CEO R. Cromwell Coulson, President and Chief Financial Officer Bea Ordonez presented at the Sidoti & Company Fall 2016 Emerging Growth Convention in New York City on behalf of the company. An archived audio webcast of the presentation is available here:


OTC Markets Group Launches Share Data Repository – Law360 (October 11, 2016)

Paltrowitz of the OTC Markets on the competitive three platforms serving 10,000 companies globally – Investor Intel (October 17, 2016)

The changing face of equity research: OTC’s new service – IR Magazine online (October 20, 2016)

OTC Markets Hosts Reg A+ Bootcamp with CrowdfundBeat – Crowdfund Insider (October 28, 2016)

OTC Markets reports Q3 results – Seeking Alpha (November 2, 2016)

Light up the Market
New OTCQX and OTCQB Companies

Welcome to the companies that joined the OTCQX Best Market and the OTCQB Venture Market in October.

The OTCQX Best Market
Ivanhoe Mines Ltd. (OTCQX: IVPAF)
MoneyOnMobile, Inc (OTCQX: MOMT)
Poydras Gaming Finance Corp. (OTCQX: PYDGF)
Swift Energy Company (OTCQX: SWTF)
Violin Memory, Inc. (OTCQX: VMEM)
Vistra Energy Corp. (OTCQX: VSTE)


The OTCQB Venture Market

Advantage Lithium Corp. (OTCQB: AVLIF)
American Education Center, Inc. (OTCQB: AMCT)
Arcturus Growthstar Technologies Inc. (OTCQB: AGSTF)
Blake Insomnia Therapeutics, Inc. (OTCQB: BKIT)
Domain Extremes, Inc. (OTCQB: DNME)
Golden Leaf Hldgs Ltd (OTCQB: GLDFF)
Great Basin Scientific, Inc. (OTCQB: GBSN)
GrowGeneration Corp. (OTCQB: GRWG)
Hispanica International Delights of America, Inc. (OTCQB: HISP)
Inbit Corp. (OTCQB: INBT)
InterCloud Systems, Inc. (OTCQB: ICLD, ICLDW)
International Frontier Resources Corp. (OTCQB: IFRTF)
Protagenic Therapeutics, Inc. (OTCQB: PTIX)
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, PVCTW)
Redstar Gold Corp. (OTCQB: RGCTF)
Rocky Mountain High Brands, Inc. (OTCQB: RMHB)
Tofutti Brands, Inc. (OTCQB: TOFB)
Ultrapetrol Bahamas Limited (OTCQB: ULTR)
Winston Gold Mining Corp. (OTCQB: WGMCF)
Yummy Flies Inc. (OTCQB: YMMF)
Zenosense, Inc. (OTCQB: ZENO)

Graduates to an Exchange Listing

Congratulations to Social Reality Inc. (NASDAQ: SRAX), which graduated from the OTCQB Venture Market to NASDAQ in October.